PD-L1 methylation restricts PD-L1/PD-1 interactions to control cancer immune surveillance

Area of Science:

• Immunology
• Cancer Biology
• Molecular Biology

Background:

• Immune checkpoint inhibitors targeting programmed cell death protein 1 (PD-1) and programmed cell death 1 ligand 1 (PD-L1) offer durable responses in some cancers.
• Reliable biomarkers for predicting anti-PD-(L)1 therapy response are currently lacking.

Purpose of the Study:

• To investigate the role of PD-L1 K162 methylation in regulating the PD-1/PD-L1 interaction.
• To identify novel biomarkers for predicting response to anti-PD-(L)1 therapy.

Main Methods:

• Investigated the enzymatic regulation of PD-L1 K162 methylation by SETD7 and demethylation by LSD2.
• Assessed the impact of PD-L1 K162 methylation on T cell activity and cancer immune surveillance.
• Analyzed PD-L1 K162 methylation as a predictive marker in non-small cell lung cancer patients treated with anti-PD-1 therapy.

Main Results:

• PD-L1 K162 methylation, regulated by SETD7 and LSD2, controls the PD-1/PD-L1 interaction.
• PD-L1 hypermethylation is associated with resistance to anti-PD-L1 therapy.
• PD-L1 K162 methylation acts as a negative predictive marker for anti-PD-1 treatment in non-small cell lung cancer.
• The ratio of PD-L1 K162 methylation to total PD-L1 is a more accurate biomarker for predicting anti-PD-(L)1 therapy sensitivity.

Conclusions:

• PD-L1 K162 methylation is a critical modification of the PD-1/PD-L1 immune checkpoint.
• This modification provides insights into the regulation of anti-cancer immune responses.
• The PD-L1 K162 methylation:PD-L1 ratio represents a promising predictive biomarker for anti-PD-(L)1 therapy.